How Neuropeptides Like CGRP, Substance P, and Opioids Control Facial and Jaw Pain
This review maps how neuropeptides in the trigeminal system either promote or suppress orofacial pain — with CGRP, substance P, and others driving pain, while opioid peptides, galanin, and oxytocin provide relief — identifying targets for new treatments.
Quick Facts
What This Study Found
Neuropeptides in the trigeminal system play distinct roles: CGRP, substance P, NPY, NKA, HK-1, and VIP are pro-inflammatory and pro-nociceptive, while opioid peptides, galanin, oxytocin, and orexin-A are analgesic — identifying multiple therapeutic targets for orofacial pain.
Key Numbers
Multiple neuropeptides reviewed including CGRP, substance P, and others involved in trigeminal pain signaling.
How They Did This
Systematic literature review summarizing current research on neuropeptide functions and mechanisms in orofacial pain, covering CGRP, substance P, opioid peptides, galanin, and other neuropeptides in the trigeminal sensory system.
Why This Research Matters
Orofacial pain conditions (TMJ disorders, trigeminal neuralgia, dental pain) affect millions and are often poorly managed by existing treatments. Understanding which neuropeptides drive versus inhibit this pain opens doors to targeted therapies — notably, CGRP-blocking drugs have already revolutionized migraine treatment and may extend to orofacial pain.
The Bigger Picture
The success of anti-CGRP antibodies for migraine demonstrates that neuropeptide-targeted therapy works. This review extends that framework to the broader orofacial pain landscape, suggesting that drugs targeting substance P, galanin agonists, or oxytocin could become next-generation treatments for facial pain conditions — potentially offering alternatives to opioid painkillers for millions of patients.
What This Study Doesn't Tell Us
Review article — synthesizes existing research rather than presenting new data. Many neuropeptide-targeting drugs for orofacial pain remain in preclinical stages. The interplay between multiple neuropeptides in vivo is more complex than studying individual peptides suggests. Clinical translation from trigeminal system research to effective therapies has historically been challenging.
Questions This Raises
- ?Can anti-CGRP antibodies (already approved for migraine) be repurposed for other orofacial pain conditions like TMJ disorders?
- ?Could combination therapy targeting both pro-pain and pain-relieving neuropeptide pathways provide superior pain control?
- ?How do individual genetic variations in neuropeptide systems explain why some patients respond to treatments while others don't?
Trust & Context
- Key Stat:
- 10+ neuropeptides mapped in the trigeminal system — divided into pro-pain (CGRP, substance P, NPY, NKA, HK-1, VIP) and analgesic (opioids, galanin, oxytocin, orexin-A) roles for orofacial pain
- Evidence Grade:
- Moderate — comprehensive review synthesizing substantial preclinical and some clinical evidence, but many proposed therapeutic targets remain unvalidated in clinical trials for orofacial pain specifically.
- Study Age:
- Published in 2024, providing an up-to-date summary of neuropeptide research in orofacial pain.
- Original Title:
- Role of neuropeptides in orofacial pain: A literature review.
- Published In:
- Journal of oral rehabilitation, 51(5), 898-908 (2024)
- Authors:
- Wang, Jian(5), Liu, Xiangtao, Gou, Junzhuo, Deng, Jing, Li, Mujia, Zhu, Yafen, Wu, Zhifang
- Database ID:
- RPEP-09473
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are neuropeptides and how do they control pain?
Neuropeptides are small protein-like molecules released by nerve cells that act as chemical messengers. In the trigeminal system (the nerve network serving the face), some neuropeptides like CGRP and substance P amplify pain signals and drive inflammation — turning up the volume on pain. Others, like opioid peptides and oxytocin, dampen pain signals — turning the volume down. The balance between these pro-pain and anti-pain peptides determines how much pain you feel.
Could this research lead to new treatments for TMJ or dental pain?
Yes — anti-CGRP antibodies have already been approved for migraine, which involves the same trigeminal nerve system. Research suggests these drugs may help with TMJ disorders and other orofacial pain conditions too. Beyond CGRP, drugs targeting substance P, galanin, or oxytocin pathways could offer additional treatment options, potentially reducing reliance on opioid painkillers.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09473APA
Wang, Jian; Liu, Xiangtao; Gou, Junzhuo; Deng, Jing; Li, Mujia; Zhu, Yafen; Wu, Zhifang. (2024). Role of neuropeptides in orofacial pain: A literature review.. Journal of oral rehabilitation, 51(5), 898-908. https://doi.org/10.1111/joor.13656
MLA
Wang, Jian, et al. "Role of neuropeptides in orofacial pain: A literature review.." Journal of oral rehabilitation, 2024. https://doi.org/10.1111/joor.13656
RethinkPeptides
RethinkPeptides Research Database. "Role of neuropeptides in orofacial pain: A literature review..." RPEP-09473. Retrieved from https://rethinkpeptides.com/research/wang-2024-role-of-neuropeptides-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.